
    
      The primary objective of this study is to define the tolerability and safety of MLN9708
      (ixazomib) administered on a day 1,8,15 every 28 day schedule up to 4mg in combination with
      fixed doses of panobinostat and dexamethasone in patients with relapsed or refractory
      myeloma.

      The secondary objectives of this study are to assess response and clinical benefit response
      rates according to international uniform response criteria and adapted EBMT criteria,
      respectively. And to assess progression-free survival (PFS) and overall survival (OS).
    
  